Foghorn Therapeutics Inc. announced that Chief Financial Officer, Allan Reine will be departing the Company to pursue another opportunity. The company has commenced a formal search for a successor. Dr. Reine?s last day as a full-time employee with Foghorn will be January 16, 2024.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
6.195 USD | +3.25% | +8.99% | -4.19% |
May. 20 | Foghorn Therapeutics Prices $110 Million Offering of Shares, Pre-Funded Warrants | MT |
May. 06 | Foghorn Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-4.19% | 256M | |
+8.29% | 115B | |
+13.20% | 107B | |
-12.63% | 22.31B | |
-3.99% | 21.6B | |
-7.16% | 18.23B | |
-39.93% | 17.62B | |
+6.71% | 14.26B | |
+33.94% | 12.37B | |
-28.92% | 8.28B |
- Stock Market
- Equities
- FHTX Stock
- News Foghorn Therapeutics Inc.
- Foghorn Therapeutics Inc. Announces Resignation of Allan Reine as Chief Financial Officer, Effective January 16, 2024